A clinical trial in the Democratic Republic of Congo is enrolling more than 250 participants to test a drug that could help prevent infection during the current Ebola outbreak. Multiple outlets report that the study is underway as researchers seek a remedy for what experts describe as the country’s deadliest Ebola outbreak.
The trial targets Bundibugyo virus, which is linked to the outbreak. PBS NewsHour adds that there is no approved vaccine or treatment specifically for this virus. The trial began in July, and it is presented as one of several efforts launched to provide protection and to slow transmission while other research continues.
While the outlets largely agree on the trial’s enrollment figure and its purpose, they differ mainly in emphasis. Some focus on the fact that recruitment is progressing as a “critical step,” while PBS NewsHour provides additional context on why the target virus is difficult to treat and situates the study among broader experimental approaches. All accounts describe the research as part of an urgent response to an ongoing outbreak.